HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Wachsman, M. Articles by Paoletti, E. Search for Related Content PubMed PubMed Citation Articles by Wachsman, M. Articles by Paoletti, E. Agricola Articles by Wachsman, M. Articles by Paoletti, E.

Antigen-presenting Capacity of Epidermal Cells Infected with Vaccinia Virus Recombinants Containing the Herpes Simplex Virus Glycoprotein D, and Protective Immunity

¹ Virology/Immunology Laboratories, Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201
² Divisions of Biophysics and Comparative Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21205
and³ Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany, New York 12201, U.S.A.

We studied the association of herpes simplex type 1 (HSV-1) glycoprotein D (gD-1) expression in epidermal cells (EC) with virus-specific immunity and protection of mice from fatal HSV-2 challenge. Vaccinia virus recombinants containing gD-1 under the control of an early (VP176) or late (VP254) vaccinia virus promoter were used. Mature gD-1 protein was expressed in VP176-infected EC and they had accessory cell function for HSV-2-induced T cell proliferation of immune lymph node cells (LNC). It was not expressed in VP254-infected EC and they did not act as accessory cells. LNC from VP176- but not VP254-immunized mice proliferated in response to HSV antigen and only VP176-immunized mice had complete long-term protection from HSV-2 challenge.

Keywords: HSV, glycoprotein D, vaccinia virus

Received 21 April 1988; accepted 5 May 1989.

This article has been cited by other articles:

				L. Aurelian Herpes Simplex Virus Type 2 Vaccines: New Ground for Optimism? Clin. Vaccine Immunol., May 1, 2004; 11(3): 437 - 445. [Abstract] [Full Text] [PDF]

				B Moss Vaccinia virus: a tool for research and vaccine development Science, June 21, 1991; 252(5013): 1662 - 1667. [Abstract] [PDF]